Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Summary

Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer). In this study HIV-patients and SOT-patients will receive 3 doses of Gardasil®9. Safety, tolerability and immunogenicity will be evaluated up to one month following the 3rd and last dose of Gardasil®9.

Timeline

Start

2018-04-04

Primary completion

2019-09-01

Completion

2020-07-15

Drugs

Indications